An observational study in Open Angle Glaucoma, sponsored by Sanoculis Ltd. Terminated at 1 site in Armenia. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Sanoculis Ltd · Observational
The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons.
A long-term (24 and 30 months) follow-up extension, prospective, non-interventional, open label study for data collection from subjects who underwent prior MIMS® inferonasal surgery, in continuation of the previous clinical investigation with the MIMS® Device (MMS-EEU-5).
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's enrollment of 44 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Sanoculis Ltd is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of subjects of Armenian descent that underwent the MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment.
Inclusion Criteria:
1. Subject who underwent MIMS® inferonasal procedure, and surgery was performed not earlier than 24 months from enrollment
Cohort that includes subjects that have undergone the MIMS® inferonasal surgery.
Device: Inferonasal Minimally Invasive Micro Sclerostomy
The Inferonasal MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the inferonasal quadrant of the eye.
Also known as: Inferonasal MIMS
Intraocular Pressure Change (Baseline to 24 months)
Change in IOP from medicated baseline to 24 months post-MIMS® surgery
Time frame: Baseline to 24 months post-MIMS® surgery
Intraocular Pressure Change (Baseline to 30 months)
Change in IOP from medicated baseline to 30 months post-MIMS® surgery
Time frame: Baseline to 30 months post-MIMS® surgery
Change in Number of Topical Intraocular Pressure Lowering Medications (Baseline to 24 Months)
Change in the number of topical IOP-lowering medications from medicated baseline to 24 months post-MIMS® surgery
Time frame: Medicated baseline to 24 months post-MIMS® surgery
Change in Number of Topical Intraocular Pressure Lowering Medications (Baseline to 30 Months)
Change in the number of topical IOP-lowering medications from medicated baseline to 30 months post-MIMS® surgery
Time frame: Medicated baseline to 30 months post-MIMS® surgery
Surgery Success Rate (24 months)
Success rate 24 months post-MIMS® surgery
Time frame: 24 months post-MIMS® surgery
Surgery Success Rate (30 months)
Success rate 30 months post-MIMS® surgery
Time frame: 30 months post-MIMS® surgery
Postoperative Complication Safety Outcomes
Late (greater than 12 months) postoperative complications
Time frame: Baseline to 30 months post-MIMS® surgery
Interventional Safety Outcomes
Late (greater than 12 months) postoperative interventions
Time frame: Baseline to 30 months post-MIMS® surgery
Plan to share: Undecided
No publications or documents are linked to this record.
The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons.
The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanoculis Ltd